One has to wonder if Forest Labs will not be a player here. Ryan, the new CEO was involved with Namenda. They would be in a position to double the majority of the current $1.6B annual revenue they get now. There is generic Namenda available for the non-daliy dose version. The modified release formulation expires in 2029
If the confirmation trial shows the results we expect, Namenda sales will be going to zero very quickly. Allergan their parent company has the international connections to make things happen quickly.
Below is an excerpt from a 2017 Bloomberg article.
"Allergan Chief Executive Officer Brent Saunders has said the drugmaker needs new medicines and possibly more deals to make up for declining sales of Namenda, which faces generic competition at the end of the year. Like the rest of the industry, Allergan -- best known for its blockbuster wrinkle treatment Botox -- had a tough year in 2016 as criticism on price increases intensified. Its stock slumped 33 percent last year."
News 
Market Data 
Discover 
AI
